Survival Analysis in Male Breast Cancer With Bone Metastasis Based on the SEER Database

Abstract

PurposeBreast cancer (BC) has been extensively and deeply studied as the number one malignant tumor in women, but its status in male patients, especially in male metastatic patients, is rarely reported. Thus, this study aimed to explore the prognosis and risk factors of male BC with bone metastasis.Patients and MethodsWe searched the Surveillance, Epidemiology, and End Results (SEER) database to identify all patients diagnosed with male BC with bone metastasis from 2010 to 2016. Risk factors of overall survival (OS) and cancer-specific survival (CSS) were analyzed by univariable and multivariable Cox analyses. We also drew Kaplan–Meier plots to show the correlation between independent risk factors and survival.ResultsA total of 207 male BC patients with bone metastasis were included for analysis. Approximately one-third of patients also had lung metastasis. Luminal A subtype comprised 58.5% of the overall patient population. These patients had a poor prognosis, with 3-year OS and CSS rates, 36.7% and 39.5%, respectively. Further analysis revealed that age ≤60 years old, luminal A or B, and surgery were independent predictors of prolonged OS and CSS. On Cox multivariable analysis, brain metastasis was associated with OS and not CSS.ConclusionWe identified four independent factors associated with prognosis in male BC patients with bone metastasis, namely age, tumor subtype, surgery, and brain metastasis. Knowing these risk factors will help clinicians make more appropriate treatment plans.

Risk stratification system and visualized dynamic nomogram constructed for predicting diagnosis and prognosis in rare male breast cancer patients with bone metastases

“…However, in our multivariate analysis, chemotherapy and radiotherapy did not significantly enhance the prognosis in MBCBM patients (P>0.05). Thankfully, our conclusion was not exceptional and was supported by Zhou et al (14). Of course, this could be owing to the absence of critical information in the SEER database, such as therapeutic drugs and doses, patient responsiveness, and compliance, preventing indepth analysis.…”

“…Therefore, they have not been incorporated into our nomograms. The article from Zhou et al also supported this result (14). Metastasis in one organ might accelerate the spread of cancer cells to other organs, and BM could considerably enhance the risk of other metastases and vice versa (4,18).…”

“…Therefore, if we timely assess the risk probability of BM in MBC patients and the survival probability of MBCBM patients in early screening, we could achieve early prevention and clinical intervention to prolong survival time. Zhou et al analyzed the prognostic factors of MBCBM patients but overlooked significant clinical variables of BC such as ER, PR, and primary site, and did not construct effective diagnostic and prognostic models (14). In this study, combined with clinical practice, we incorporated more variables related to MBC.…”

“…This has a substantial detrimental impact on patients' quality of life and mental health, as well as increasing social burden and triggering public anxiety. To date, there are many published reports on FBC with BM, but few on the clinical characteristics and prognostic survival of MBC with BM (MBCBM) (11)(12)(13)(14).…”

Development and validation of a prognostic nomogram model for HER2-positive male breast cancer patients

“…However, there is minimal evidence to support the hypothesis that men with HER2-positive breast cancer bene t from surgery. However, studies have shown that surgery brings longer survival for HER2-positive breast cancer patients [23]as well as men with breast cancer [24]. It is well-known that chemotherapy is an important treatment for malignant tumors.…”